drugset / Trial / NCT00992563
WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, and effects of investigational drug AL-39324 for the treatment of wet AMD.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AL-39324 | Unknown | — | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 10 mg/ml | Intravitreal |